Table 3 –

Overall survival summary by cohort

Cohorts		HR (vs. <1.8 pts/year)	95% CI			P-value
Cohort A All advanced PC patients (T4 or N+ or M+)	1.8–3.3 pts/year	0.970	0.907	-	1.036	0.3643
	3.4–5.6 pts/year	0.947	0.890	-	1.007	0.0839
	>5.6 pts/year	0.821	0.770	-	0.876	<.0001
Cohort B1 M0 patients	1.8–3.3 pts/year	0.849	0.735	-	0.981	0.0265
	3.4–5.6 pts/year	0.827	0.723	-	0.946	0.0055
	>5.6 pts/year	0.698	0.612	-	0.796	<.0001
Cohort B2 M0 patients who underwent active treatment	1.8–3.3 pts/year	0.938	0.799	-	1.101	0.4303
	3.4–5.6 pts/year	0.868	0.746	-	1.009	0.066
	>5.6 pts/year	0.738	0.637	-	0.854	<.0001
Cohort C1 M1 patients	1.8–3.3 pts/year	0.977	0.915	-	1.043	0.491
	3.4–5.6 pts/year	0.964	0.907	-	1.024	0.2323
	>5.6 pts/year	0.839	0.787	-	0.895	<.0001
Cohort C2 M1 patients who underwent active treatment	1.8–3.3 pts/year	1.001	0.930	-	1.077	0.9802
	3.4–5.6 pts/year	0.998	0.933	-	1.068	0.9638
	>5.6 pts/year	0.870	0.813	-	0.931	<.0001
Cohort C3 M1 patients who underwent active treatment, and with known metastatic sites	1.8–3.3 pts/year	0.987	0.872	-	1.117	0.8346
	3.4–5.6 pts/year	1.026	0.916	-	1.149	0.6541
	>5.6 pts/year	0.864	0.773	-	0.966	0.0099
Cohort A Sensitivity analysis adjusted for Gleason score	1.8–3.3 pts/year	0.978	0.906	-	1.056	0.5747
	3.4–5.6 pts/year	0.940	0.874	-	1.012	0.0993
	>5.6 pts/year	0.812	0.754	-	0.875	<.0001
Cohort A Sensitivity analysis adjusted for facility type	1.8–3.3 pts/year	0.966	0.901	-	1.035	0.3245
	3.4–5.6 pts/year	0.951	0.887	-	1.019	0.1512
	>5.6 pts/year	0.855	0.791	-	0.925	<.0001